Test detects five most commonly misused and abused prescription drugs; five-minute results will facilitate rapid interventions in prescription drug abuse. Read More »

The last patient in the Phase II BEKINDA (RBH-102) study has completed the treatment and follow-up, RedHill Biopharma Ltd. announced on Monday. Read More »

Pharmaceutical Care Management Association (PCMA) President and CEO Mark Merritt has written directly to U.S. Food and Drug Administration Commissioner Scott Gottlieb to offer the association’s concise solution for fast-tracking “common-sense” improvements to the nation’s opioid abuse policy. Read More »

Amgen of Thousand Oaks, California and Array BioPharma of Boulder, Colorado recently created a cooperative contract to develop innovative drugs aimed at combating autoimmune disorders after Array’s breakthrough discovery of certain target and lead inhibitors. Read More »

Launching a four-year research program to develop diabetes and obesity treatments, PreveCeutical Medical Inc. of Vancouver, British Columbia recently signed an agreement with UniQuest Pty Ltd. of the University of Queensland in Australia. Read More »

Chronic hepatitis C virus (HCV) patients have a new treatment option with the approval of Vosevi (sofosbuvir 400 mg/velpatasvir 100 mg/voxilaprevir 100 mg) by the U.S. Food and Drug Administration. Read More »

PRN1008 — acting as a reversible covalent Bruton’s Tyrosine Kinase (BTK) inhibitor — has attained orphan drug designation by the U.S. Food and Drug Administration (FDA) for treating pemphigus vulgaris, its producer Principia Biopharma Inc. announced recently. Read More »

Shifting from a “pill-centric to patient-centric” focus, cloud-based prescription service is now available for North Carolina consumers — enabling streamlined information sharing and care coordination — provider PrescribeWellness announced recently from its hub in Irvine, California. Read More »

Joining forces with experienced clinicians from Novia Strategies, GE Healthcare recently acquired the 22-year-old California-founded consulting group to enhance its capability for driving optimal outcomes through organizational improvement. Read More »

GSK (GlaxoSmithKline PLC) recently commenced follow-up to approval gained from the U.S. Food and Drug Administration for shipping vaccines combating influenza to nationwide health care providers in advance of the 2017-18 flu season. Read More »

Demonstrating excellence in overcoming cultural barriers to quality care, Medicaid managed health care plan AmeriHealth Caritas Louisiana of Baton Rouge recently merited an honor from the National Committee for Quality Assurance (NCQA). Read More »

Lannett Company Inc. of Philadelphia recently obtained and subsequently announced FDA approval of its Abbreviated New Drug Application (ANDA) for Cyproheptadine Hydrochloride Syrup (Cyproheptadine Hydrochloride Oral Solution, USP) in 2 mg/5 mL dosage form. Read More »

Magellan Health Inc. struck a deal this month to acquire Senior Whole Health, a provider of Medicare and Medicaid to dual-eligible clients in Massachusetts and New York. Read More »

Novoteris LLC's Phase 2 clinical trial application for inhaled nitric oxide as a treatment for cystic fibrosis has been approved by both the U.S. Food and Drug Administration and the Therapeutic Products Directorate of Health Canada. Read More »

Pfizer Inc. recently announced that the U.S. Food and Drug Administration (FDA) accepted the company’s supplemental New Drug Application (sNDA) for Sutent. Read More »

HedgePath Pharmaceuticals Inc. (HPPI) recently announced that the U.S. Food and Drug Administration (FDA) granted the company’s Type-C Guidance Meeting Request for further guidance on HPPI’s Phase 2(b) clinical trial analyzing SUBA-Itraconazole (SUBA-Cap) oral capsule usage in patients with Basal Cell Carcinoma Nevus Syndrome (BCCNS), also known as Gorlin Syndrome. Read More »

AbbVie recently announced positive follow-up results for its pivotal Phase 3 Resonate trial, which evaluated Imbruvica as a treatment for patients with relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic leukemia (CLL/SLL). Read More »

Amgen's Xgeva Phase 3 study, the largest international multiple myeloma trial ever conducted, met its primary endpoint by demonstrating that the drug is non-inferior to zoledronic acid in delaying the time to first on-study skeletal-related event in patients with multiple myeloma. Read More »

Merck KGaA will collaborate with F-Star, a biopharmaceutical company in the United Kingdom, to develop and commercialize five bispecific immuno-oncology antibodies. Read More »

Amgen's Phase 2 study evaluating Imlygic combined with Yervoy as a treatment for patients with unresectable Stage IIIB-IV met its​ primary endpoint. Read More »